MFIMFI
CRL icon

Mesirow Financial Investment Management - Fixed Income’s Charles River Laboratories CRL Stock Holding History

Mesirow Financial Investment Management - Fixed Income’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-7,750
Closed -$1.66M – 37
2022
Q2 		$1.66M Buy
+7,750
New +$1.89M 0.21% 106

Other funds holding CRL

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Kayne Anderson Rudnick Investment Management
Kayne Anderson Rudnick Investment Management Los Angeles, California $34B AUM 6.31% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $59.7B AUM 29.08% 1-Year Est. Return
JSP
Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return

Mesirow Financial Investment Management - Fixed Income's CRL Position: Q3 2022 in Review

Mesirow Financial Investment Management - Fixed Income sold out of Charles River Laboratories (CRL) in Q3 2022, closing a stake of 7,750 shares — an estimated $1.66M sold.

Mesirow Financial Investment Management - Fixed Income first reported a position in CRL in Q2 2022 and held it in 1 quarter. The position peaked at $1.66M in Q2 2022. 584 funds tracked by Wall St. Rank hold CRL as of Q3 2022.

  • Mesirow Financial Investment Management - Fixed Income reported no remaining Charles River Laboratories position as of Q3 2022 after selling out during the quarter.
  • Mesirow Financial Investment Management - Fixed Income sold 7,750 Charles River Laboratories shares in Q3 2022, an estimated $1.66M.
  • Mesirow Financial Investment Management - Fixed Income first reported a position in Charles River Laboratories in Q2 2022 and held it in 1 quarter.
  • Mesirow Financial Investment Management - Fixed Income's Charles River Laboratories position peaked at $1.66M in Q2 2022.
  • 584 funds tracked by Wall St. Rank held Charles River Laboratories as of Q3 2022.

Based on Mesirow Financial Investment Management - Fixed Income's 13F filing for Q3 2022, filed 8 Nov 2022.